Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA minor groove alkylation refers to the covalent modification of DNA bases within the minor groove of the double helix by alkylating agents. This process disrupts DNA replication and transcription, making it a target for anticancer drugs. Alkylating agents react with nucleophilic sites on DNA bases, particularly adenine N3, leading to cytotoxic lesions. The selectivity of alkylation can be enhanced using carrier molecules. The resulting damage triggers various DNA repair pathways, but if unrepaired or misrepaired, it can lead to mutagenesis and cell death. Minor-groove-directed alkylations are particularly effective at blocking RNA polymerase II-mediated transcription. This mechanism underlies the utility of alkylating agents as cytotoxic chemotherapeutics. Several repair pathways are involved, including Base Excision Repair (BER) and Nucleotide Excision Repair (NER).
Covalent modification of DNA bases in the minor groove, leading to transcriptional stalling, mutagenesis, and activation of DNA repair pathways.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA Minor Groove (Alkylation) (N/A).